Linkedin
Facebook
Twitter
μια πρωτοβουλία της IPSEN 
Αυτές οι πληροφορίες προορίζονται για γενική πληροφόρηση και ενημέρωση του κοινού και σε καμία περίπτωση δεν μπορούν να υποκαταστήσουν την συμβουλή ιατρού ή άλλου αρμόδιου επαγγελματία υγείας.
References
1. Canadian Cancer Society. The neuroendocrine system. https://www.cancer.ca Accessed May 22, 2019.
2. Sackstein PE, O’Neil DS, Neugut AI, et al. Epidemiologic trends in neuroendocrine tumors: an examination of incidence rates and survival of specific patient subgroups over the past 20 years. Seminars in Oncol. 2018;4(13):249–58.
3. Ramirez RA, Chauhan A, Gimenez J, et al. Management of pulmonary neuroendocrine tumors. Rev Endocr Metab Disord. 2017;18(4):433-442.
4. National Cancer Institute. Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)-Patient Version. 2018. https://www.cancer.gov. Accessed October 22, 2018.
5. National Cancer Institute. Pheochromocytoma and paraganglioma treatment (PDQ®)-patient version. 2017. https://www.cancer.gov. Accessed October 23, 2018.
6. Schernthaner-Reiter MH, Trivellin G, Stratakis CA. MEN1, MEN4, and Carney complex: pathology and molecular genetics. Neuroendocrinology. 2016;103: 18e31.
7. Cancer.NET Editorial Board. Neuroendocrine Tumor of the Pancreas: Symptoms and Signs. 2017. https://www.cancer.net. Accessed October 22, 2018.
8. Singh S, Granberg D, Wolin E, et al. Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs. J Glob Oncol. 2016;2(1):43–53.
9. National Institute of Diabetes and Digestive and Kidney Diseases. Your digestive system and how it works. https://www.niddk.nih.gov. Accessed October 19, 2018.
10. Modlin IM, Latich I, Kidd M, et al. Therapeutic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol. 2006; 4(5): 526-47, 2006.